Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter
Abstract Adverse side effects of cancer agents are of great concern in the context of childhood tumors where they can reduce the quality of life in young patients and cause life-long adverse effects. Synergistic drug combinations can lessen potential toxic side effects through lower dosing and simul...
Main Authors: | Branka Radic-Sarikas, Melinda Halasz, Kilian V. M. Huber, Georg E. Winter, Kalliopi P. Tsafou, Theodore Papamarkou, Søren Brunak, Walter Kolch, Giulio Superti-Furga |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2017-06-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-017-03129-6 |
Similar Items
-
Evaluation of the possibility of combining YM155 with Amiodarone for the future YM155-based anticancer clinical trials
by: Ju-YaTsai, et al.
Published: (2016) -
Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines
by: Martin Michaelis, et al.
Published: (2020-03-01) -
YM155 induces EGFR suppression in pancreatic cancer cells.
by: Young-Soon Na, et al.
Published: (2012-01-01) -
Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer
by: J. Robert McCorkle, et al.
Published: (2021-01-01) -
Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
by: J Robert McCorkle, et al.
Published: (2021-01-01)